Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Kuros Biosciences AG

www.kuros.ch

Latest From Kuros Biosciences AG

Family Offices Boost Life Sciences Partners’s Over-Subscribed Fifth Fund

Family offices are increasing their exposure to Europe’s life sciences sector by investing in venture capital funds, including the just-closed over-subscribed fifth fund from Life Sciences Partners.

Business Strategies Europe

Deals Shaping The Medical Industry, September 2015

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in August 2015.

BioPharmaceutical Medical Device

FINANCE ROUNDUP: Global Blood Doubles Post-IPO, GlobeImmune Considers Options, VC Deals Surge

Global Blood Therapeutics launched an initial public offering at $20 per share and its stock price more than doubled to $43.11 at the end of its first day of trading on Aug. 12, proving that investors may be concerned about a biotechnology bubble, but they're not overly worried that it will burst soon.

Gastrointestinal Metabolic Disorders

Alzheimer’s R&D In Brief: Roche’s Crenezumab Misses Endpoints, Novartis Plans Large New Genetic Study

In data presented at the Alzheimer's Association International Conference in Copenhagen, held July 12-17, Roche’s anti-amyloid beta antibody misses endpoints in two Phase II studies, but there were some promising signs of efficacy.

BioPharmaceutical Clinical Trials
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Switzerland
  • Parent & Subsidiaries
  • Kuros Biosciences AG
  • Senior Management
  • Joost de Bruijn , PhD, CEO
    Michael Grau, CFO
    Philippe Saudan, PhD, Chief Dev. Officer
    Alistair Irvine, PhD, CBO
  • Contact Info
  • Kuros Biosciences AG
    Phone: (41) 44 733 47 47
    Wagistrasse 25
    Schlieren, 8952
    Switzerland
Advertisement
Advertisement
UsernamePublicRestriction

Register